|Dr. Roger Crystal||CEO & Director||1.38M||N/A||1976|
|Mr. David D. O'Toole||Chief Financial Officer||539.25k||N/A||1959|
|Dr. Phil Skolnick||Chief Scientific Officer||814.09k||N/A||1947|
|Lisa Sher||Sr. Director of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Rahsaan Thompson||Gen. Counsel||N/A||N/A||N/A|
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; eating disorders, including bulimia nervosa and binge eating disorders; alcohol use disorders; acute cannabinoid overdose; opioid use disorders; and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California.
Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.